Lead Product YuuthTM – Rebooting the Genetic Program to Restore Youthful Beauty
Ponce Therapeutics is using advanced, proprietary technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead programs utilize proprietary, state-of-the-art biotechnology platforms to restore the youthful balance of aged or “senescent” and young cells in the skin, targeting the senescent cells for elimination. This provides a “reboot” of one’s genetic program to turn the clock on one’s skin back to its youthful exuberance.
Proprietary Platform
Targeting Senescent Cells for Elimination
Elimination of pro-inflammatory senescent cells has been shown to suppress cancer and rejuvenate tissues by restoring stem cell niches to their healthy state.

Clinical Pipeline
Development of our lead program, PT-001mn
Lead program, PT-001mn, to deliver p16-directed riCasp9 to keratinocytes in treating Bowen’s lesions using proprietary delivery technology.